TSO3 File Passes US Regulatory Acceptance Review - STERIZONE® 125L+ Sterilizer 510(k) request to now undergo substantive review process

TSO₃ Inc. (TSX:TOS.TO ) ("TSO₃" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that its new simplified filing to the US regulatory agency for clearance to commercialize the STERIZONE^® 125L+ Sterilizer in that market, passed the acceptance review step, ensuring that the file is administratively complete as per the Agency's requirements.

The Agency has granted TSO₃'s file a 510(k) number and will now initiate the "substantive review" process. As per the Agency's most recent guidelines dated December 31, 2012, the Agency targets to respond within 60 days of filing, while maximum agency clock is of 90 days. The Company has 180 days total clock to respond to Agency questions. Complete US regulatory guidelines for 510(k) clearances can be found at:

http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089735.htm

EDAP Submits U.S. FDA Pre-Market Approval Application for Ablatherm(R)-HIFU for Treatment of Low Risk, Localized Prostate Cancer

EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, announced today the submission of its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) on January 31, 2013 for the Company's Ablatherm-HIFU (High Intensity Focused Ultrasound) for treatment of low risk, localized prostate cancer. EDAP's PMA submission includes data from the ENLIGHT study, a multi-center U.S. Phase II/III clinical trial that completed the two year follow-up needed to evaluate its primary endpoint in August 2012, as well as data from the Company's extensive worldwide database of treatment information and follow-up data from patients who have undergone HIFU therapy for prostate cancer.

FDA Clears First Autonomous Telemedicine Robot for Hospitals

RP-VITA™, by iRobot and InTouch Health, enables doctors to provide patient care from anywhere in the world via a telemedicine solution

iRobot Corp. (IRBT), a leader in delivering robotic solutions, announced that the RP-VITA Remote Presence Robot has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in hospitals. RP-VITA is the first autonomous navigation remote presence robot to receive FDA clearance.

RP-VITA is a joint effort between two industry leaders, iRobot and InTouch Health. The robot combines the latest in autonomous navigation and mobility technologies developed by iRobot with state-of-the-art telemedicine and electronic health record integration developed by InTouch Health.

Dynatronics Announces Reverse Stock Split

Dynatronics Corporation (DYNT) today announced that on December 17, 2012, at the Company's annual meeting, the shareholders approved a one-for-five reverse stock split of the Company's common stock.  Approximately 93% of the votes cast were in favor of the reverse split which becomes effective today.

"After careful analysis, our board of directors determined that the best course of action for shareholders was to maintain our Nasdaq listing where we have traded for the past 28 years," stated Kelvyn H. Cullimore, Jr., chairman and president of Dynatronics.  "Our research showed that staying on Nasdaq provides greater liquidity through higher trading volumes, as well as tighter spreads between bid and ask prices, more market makers and overall better investor confidence compared to trading in the over-the-counter market as a result of being delisted from Nasdaq."